In a 64-year-old woman with a family history of ovarian cancer and unexplained abdominal symptoms, what is the best initial method to rule out ovarian cancer?

Best Initial Diagnostic Approach for Suspected Ovarian Cancer

For a 64-year-old woman with unexplained abdominal symptoms and family history of ovarian cancer, the best initial approach combines serum CA-125 measurement with transvaginal and transabdominal ultrasound performed by an experienced examiner, followed by CT imaging of the chest, abdomen, and pelvis. 1

Recommended Diagnostic Algorithm

Initial Testing (Perform Simultaneously)

• Serum CA-125 measurement is the standard first-line tumor marker, elevated in approximately 85% of advanced ovarian cancer cases 1
• Transvaginal and transabdominal ultrasound should be performed by an expert examiner using validated risk models 1
• CT scan of thorax, abdomen, and pelvis to complete clinical staging and aid surgical planning 1

Important Caveats About CA-125

CA-125 has significant limitations that clinicians must understand 1:

• Only elevated in approximately 50% of early-stage (FIGO Stage I) cases 1
• Can be falsely elevated in benign conditions including endometriosis, ovarian cysts, pelvic inflammatory disease, menstruation, and uterine fibroids 1
• Also elevated in non-gynecological malignancies 1

For mucinous tumors specifically, add serum CEA and CA 19-9 measurements to distinguish primary ovarian tumors from gastrointestinal metastases, with endoscopy indicated if the CA-125/CEA ratio is ≤25:1 1

Ultrasound Interpretation

The most recent evidence supports using ultrasound-based diagnostic models rather than CA-125 alone 1:

• IOTA (International Ovarian Tumor Analysis) models including the Simple Rules risk model or ADNEX model are superior to CA-125, HE4, or Risk of Malignancy Index for distinguishing benign from malignant ovarian tumors 1
• High-risk ultrasound features include: complex ovarian mass with solid and cystic components, internal echoes and/or septations, ascites, or evidence of peritoneal metastases 2

Recent prospective data from the ROCkeTS study demonstrates that IOTA ADNEX at 10% threshold achieved 96.1% sensitivity in postmenopausal women compared to 82.9% for Risk of Malignancy Index, making it the superior diagnostic approach 3

Why This Differs from Screening Recommendations

Critical distinction: This patient is symptomatic, not undergoing screening 4:

• The USPSTF and all major organizations recommend against routine screening in asymptomatic women due to poor positive predictive value (approximately 2%), high false-positive rates, and potential for unnecessary surgery 4
• However, the American College of Obstetricians and Gynecologists specifically recommends that symptomatic women with abdominal or pelvic pain and unexplained symptoms should be evaluated with pelvic examination, CA-125, and ultrasound 4

Additional Considerations for This Patient

Family History Impact

With a family history of ovarian cancer, this patient may have elevated baseline risk 1:

• Consider genetic counseling and testing for BRCA1/2 mutations (associated with 16-65% increased ovarian cancer risk) and Lynch syndrome (10-12% lifetime risk) 1
• Women with strong family history may warrant referral to academic centers for specialized evaluation 4

Symptom Recognition

Recognized symptoms requiring evaluation include 1, 5:

• Abdominal/pelvic pain
• Abdominal distension or bloating
• Constipation or diarrhea
• Urinary frequency
• Vaginal bleeding
• Fatigue
• Early satiety, nausea, anorexia, dyspepsia (in advanced disease)

When to Add MRI

MRI with IV contrast becomes the modality of choice when 6:

• Ultrasound findings are indeterminate
• Organ of origin is uncertain
• Distinction between benign and malignant is unclear
• MRI demonstrates superior specificity compared to CT for characterizing indeterminate adnexal masses 6

Definitive Diagnosis

Pathological examination of adequate tumor tissue from diagnostic biopsy or surgical specimen is required for definitive diagnosis 1:

• Cytological assessment alone is insufficient 7
• If neoadjuvant chemotherapy is planned, ensure adequate tissue is obtained before treatment for genetic tumor testing 1
• Cytological assessment of pleural effusion should be performed if present 1

Common Pitfalls to Avoid

• Do not rely on CA-125 alone - it misses 50% of early-stage cancers and has poor specificity 1
• Do not perform CT as the initial imaging modality - ultrasound is superior for initial characterization 1, 6
• Do not confuse screening recommendations with symptomatic evaluation - symptomatic women require full diagnostic workup regardless of screening guidelines 4
• Do not delay referral to gynecologic oncology if imaging and biomarkers are suspicious for malignancy 8